Stage IIIB Breast Cancer Completed Phase 2 Trials for Pertuzumab (DB06366)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01959490Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast CancerBasic Science